How Does GHK-Cu Work? Mechanism of Action, Per the Research

GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). Questions about how it works usually collapse into two different layers of evidence: a well-characterised coordination chemistry, and a much larger set of proposed biological effects that have mostly been mapped in cultured cells, rodents and invertebrates. This page separates those layers and labels the model system behind each claim. It is descriptive only. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or compound.

The Established Layer: A Copper-Binding Tripeptide

The chemistry is the least contested part of the picture. GHK is a short sequence whose histidine imidazole, terminal amine and backbone nitrogen form a coordination pocket for divalent copper, producing the GHK-Cu(II) complex. Reviews of the tripeptide describe this copper affinity as the organising feature of its pharmacology, positioning GHK as a physiological carrier that can accept copper from albumin and deliver it toward cells (PMID 22666519). Because copper is a cofactor for enzymes involved in connective-tissue cross-linking, mitochondrial respiration and antioxidant defence, a molecule that moves copper has, in principle, access to many downstream systems.

That logic is also the main caveat. Copper delivery is a plausible upstream event; the specific downstream consequences in an intact human remain largely inferred rather than directly measured. A 2026 review of the tripeptide in aesthetic medicine summarised its regenerative pharmacology while noting that much of the supporting work sits in preclinical and small-scale settings (PMID 42619529).

A Named Molecular Target: Peroxiredoxin 6

One of the more concrete mechanistic findings comes from silicosis modelling. Researchers reported that GHK-Cu attenuated lung inflammation and fibrosis in an experimental silicosis model by targeting peroxiredoxin 6, an antioxidant enzyme with both peroxidase and phospholipase A2 activity (PMID 38879894). That work is significant for mechanism discussion because it moves beyond "GHK-Cu reduced oxidative stress" toward an identified protein interaction in a defined disease model. It was, however, preclinical work, and a single identified target in one tissue context does not establish that the same interaction dominates elsewhere.

Redox and Inflammatory Signalling in Animal Models

Several independent animal studies converge on an antioxidant and anti-inflammatory signature, each in a different injury model.

• Acute lung injury. A mouse study reported that the GHK-Cu complex ameliorated lipopolysaccharide-induced acute lung injury (PMID 27517151).
• Pulmonary fibrosis. In bleomycin-induced pulmonary fibrosis, the study described protective effects attributed to anti-oxidative stress and anti-inflammation pathways (PMID 31809714).
• Colitis. Researchers explored beneficial effects of GHK-Cu in an experimental model of colitis and investigated the underlying mechanisms (PMID 40672369).

Read together, these reports suggest the complex behaves as a modulator of inflammatory and redox signalling rather than as a single-receptor agonist. No classical GHK-Cu receptor has been defined in the way that, for example, a G-protein-coupled receptor is defined for a hormone peptide; the reviewed literature instead frames activity in terms of copper handling, enzyme interaction and transcriptional change (PMID 22666519). That distinction matters when the phrase "mechanism of action" is used loosely — the published model is a network effect, not a lock-and-key receptor story.

Mitochondrial Function and Stress-Response Transcription Factors

Invertebrate work has added a transcriptional dimension. In Caenorhabditis elegans, researchers reported that GHK-Cu delayed ageing through coordinated regulation of mitochondrial function and activation of the DAF-16 and SKN-1 pathways (PMID 42084774). DAF-16 and SKN-1 are the nematode counterparts of the FOXO and Nrf2 stress-response factors in mammals, so the finding is often read as supporting an Nrf2-type antioxidant axis. The inference is reasonable but remains an inference: the study was performed in a nematode, and conservation of a pathway name does not guarantee conservation of the response in human tissue.

Broader gerontology reviewing has placed GHK-Cu among peptides discussed for mechanisms relevant to healthy ageing, while emphasising that mechanistic plausibility and clinical demonstration are separate standards (PMID 42021992).

Matrix Remodelling and Regenerative Signalling

The dermatological and aesthetic literature is where GHK-Cu is most frequently discussed. A 2026 review of its regenerative potential in aesthetic medicine summarised proposed actions on extracellular matrix turnover and tissue repair signalling (PMID 42619529). Mechanistically, copper-dependent enzymes such as lysyl oxidase participate in collagen and elastin cross-linking, which is the usual bridge drawn between copper delivery and matrix biology; the reviews describe this as a proposed pathway rather than a quantified human effect (PMID 22666519).

Musculoskeletal reviewing has been more cautious still. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance assessed safety and efficacy across this class and described substantial gaps between preclinical mechanism and controlled human outcome data (PMID 41966639).

Nervous System Work

Interest in neurological applications follows the same antioxidant logic. A review discussed the human tripeptide GHK-Cu in the prevention of oxidative stress and degenerative conditions of ageing, including implications for cognitive health (PMID 22666519). A separate preprint reported that behavioural and neuropathological features of Alzheimer's disease were attenuated in 5xFAD mice treated with intranasal GHK peptide (PMID 38045355). That report was posted as a bioRxiv preprint, meaning it had not completed peer review at posting, and it used a transgenic mouse model — a system that has historically produced findings that did not reproduce in human trials.

Established Versus Proposed: A Side-by-Side

Why Route and Formulation Keep Appearing in Mechanism Discussions

Mechanism is inseparable from exposure. GHK-Cu is a small, charged, hydrophilic complex, and the preclinical literature has used routes selected for the model rather than for human convenience — for example, the Alzheimer's preprint used an intranasal route in mice (PMID 38045355), while lung-injury work used systemic administration in rodents (PMID 27517151). Reviews of therapeutic peptides in orthopaedics have highlighted delivery, stability and bioavailability as recurring obstacles that separate a promising in-vitro mechanism from a usable therapeutic (PMID 41490200). No dosing information is provided on this page, and none should be inferred from the model systems described.

Adverse Events and Safety: What Studies Report

Safety data for GHK-Cu specifically are thin outside topical cosmetic contexts. A 2026 review examining safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance reported that many peptides circulating in this space lack regulatory approval and lack controlled human safety characterisation (PMID 41966639). A review of peptide supplements in sports medicine similarly reported concerns about product purity, unverified claims and the absence of robust trial evidence (PMID 42578445). Orthopaedic reviewing described applications and challenges for therapeutic peptides, including the regulatory and quality-control issues that accompany non-approved preparations (PMID 41490200). Because copper is biologically active in its own right, copper homeostasis is a theoretical consideration that the gerontology review literature raises alongside mechanism discussion (PMID 42021992).

How to Read the Mechanism Literature Critically

1. Check the species. Findings from mice, rats and nematodes describe what happened in those organisms, as in the nematode ageing study (PMID 42084774).
2. Check the publication stage. Preprints such as the 5xFAD mouse report had not completed peer review at posting (PMID 38045355).
3. Separate target identification from clinical effect. Identifying peroxiredoxin 6 as a target explains a possible pathway; it does not forecast a human outcome (PMID 38879894).
4. Weight reviews appropriately. Narrative reviews summarise and interpret; they do not generate new controlled data (PMID 42619529).

The Short Version

The copper-binding chemistry of GHK-Cu is established. A specific enzyme target has been identified in one preclinical disease model (PMID 38879894), and antioxidant, anti-inflammatory and stress-pathway effects have been reported across several animal and invertebrate systems (PMID 31809714, PMID 42084774). What remains unestablished is whether these mechanisms translate into measurable human clinical effects, a gap that the peptide class reviews describe directly (PMID 41966639). Mechanistic plausibility and demonstrated clinical benefit are different claims, and the published record currently supports the first far more strongly than the second.

References

• The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health (Oxidative Medicine and Cellular Longevity, 2012)
• The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice (Oncotarget, 2016)
• Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways (Life Sciences, 2020)
• Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide (bioRxiv preprint, 2023)
• The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6 (Redox Biology, 2024)
• Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms (Frontiers in Pharmacology, 2025)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)
• The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways (Biogerontology, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)
• The Regenerative Potential of GHK-Cu in Aesthetic Medicine (Aesthetic Surgery Journal, 2026)